Orchestra BioMed (OBIO) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Orchestra BioMed (OBIO) has outperformed Relmada Therapeutics (RLMD) over the past year, gaining 107.3% versus a gain of 63.3%. Over five years, OBIO leads with a -42.5% price change compared with -86.2% for RLMD. Relmada Therapeutics is the larger company by market cap ($346.7 million vs $340.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OBIO | RLMD |
|---|---|---|
| Share price | $5.66 | $3.25 |
| Market cap | $340.19M | $346.68M |
| 1-day change | -3.08% | -0.91% |
| YTD return | +36.39% | -32.71% |
| 1-year return | +107.33% | +63.32% |
| 5-year return | -42.54% | -86.25% |
| EPS (TTM) | $-0.86 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.50 | $8.00 |
| 52-week low | $2.78 | $1.80 |
| Distance from 52-week high | -12.92% | -59.38% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +119.61% | +230.77% |
| Average volume | 299.24K | 1.33M |
| Shares outstanding | 60.11M | 106.67M |
| Employees | 86 | 17 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OBIO has outperformed RLMD by 44.0 percentage points over the past year.
About Orchestra BioMed
OBIO stock →Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Health Care · Medicinal Chemicals and Botanical Products · 86 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
OBIO vs RLMD FAQ
Which is bigger, Orchestra BioMed or Relmada Therapeutics?
Relmada Therapeutics (RLMD) is larger, with a market capitalization of $346.68M compared with $340.19M for Orchestra BioMed (OBIO).
Which stock has performed better over the past year, OBIO or RLMD?
OBIO returned +107.33% over the past 12 months, compared with +63.32% for RLMD (price return, excluding dividends). Past performance does not predict future results.
Are Orchestra BioMed and Relmada Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Medicinal Chemicals and Botanical Products for Orchestra BioMed and Biotechnology: Pharmaceutical Preparations for Relmada Therapeutics.